Interview With Christi Myers

Entheon Biomedical CEO Timothy Ko (CSE: ENBI) (OTC: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction with DMT.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.

Entheon Biomedical is developing a DMT-assisted therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives.

Entheon’s DMT clinical trial later this year will put it in direct competition with MindMed (MMED /MMEDF), who is also planning on launching a DMT clinical trial later this year.

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

For any potential collaborations, please reach us at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video.

https://entheonbiomedical.com/
CSE: ENBI | OTCQB: ENTBF

This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/

#EntheonBiomedical​​​ ​#Entheon​​​ #PsychedelicStocks

What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.

MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.

MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #JNJ #MNMD

Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:

MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.

Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results

: file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…​
Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…​

Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/​
Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…​

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…​
https://benzinga.grsm.io/thepsychedel…​

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed​ #MindMedStock​ #MNMD